Tasburgh Lodge Surgery is part of the Research Site Initiative Scheme. The scheme is developed by the Primary Care Clinical Research Network in collaboration with the Royal College of General Practitioners to establish and maintain capacity and capability for practices in the locality to contribute to NIHR (National Institute for Health Research) portfolio research.

The lead GP taking part in the research is our senior partner, Dr Ko, with support from our managing partner, Jackie Rotherham. 

We are currently taking part in the following research projects:

1) TIME Study: 

The British Hypertension Society has asked our practice to take part in an interesting study. The study is to see if it is better for patients to take blood pressure tablets in the morning or in the evening. We have agreed to help because we think this is an important question to answer.

2) Helicobacter Eradication Asprian Trial (HEAT):

The HEAT trial is a large randomised controlled trialdesigned to investigate whether a one week course of H. pylori eradication will reduce the incidence of gastric ulcer bleeding in patients using aspirin ≤325mg daily.

3) Latent Autoimmune Diabetes in Adults Study (LADA):

Professor Kamlesh Khunti, from the Leicester Diabetes Centre, together with researchers from the Children’s Hospital of Philadelphia Research Institute, USA are conducting a study looking at the genetic causes of Latent Autoimmune Diabetes in Adults, or ‘LADA’ for short. Latenet Autoimmune Diabetes is a form of diabetes that not many people are aware of and is poorly understood. We feel it is important to gain better understanding of the condition and help scientist develop newer and more effective treatments for diabetes.

4) E-Cigarette Study: 

Perceptions on the role of E-Cigarettes and E-Cigarette resources: A Qualitative Study

5) STILTS2 (University of Cambridge):

A study examining the common and rare genetic variants associated with thinness. It is looking for anyone with BMI less than 18kg/m2 but excluding known history of eating disorders, renal, liver or gastrointestinal disease. 

6) Febuxostat vs Allopurinol Streamlined Trial for Gout Treatment Study (FAST):

Safety study comparing the relative cardiac safety of febuxostat vs allopurinol . Patients with clinically diagnosed symptomatic hyperuricaemia who are 60yrs and over with at least one additional CV risk factor and who are currently prescribed allopurinol for chronic hyperuricaemia.